Seeking Alpha

Medivation (MDVN) resumed trading just before the close, up 7.6% on the back of the FDA...

Medivation (MDVN) resumed trading just before the close, up 7.6% on the back of the FDA announcement of an early approval for it and Astellas Pharma's enzalutamide capsules for the treatment of patients with metastatic castration-resistant prostate cancer.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|